Lutris Pharma Reports Durable Phase 2 Benefit for LUT014 Gel in EGFR Inhibitor Rash
Lutris Pharma presented updated Phase 2 data at EADV showing durable, mechanism-directed benefit of LUT014 topical gel for acneiform rash caused by EGFR inhibitor therapy.